Navigation Links
Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer

IRVING, Texas--(BUSINESS WIRE)--Apr 25, 2007 - Reata Pharmaceuticals, Inc. today announced the publication of a review article covering the company's Synthetic Triterpenoid programs in the May 2007 issue of the prestigious journal "Nature Reviews Cancer."

The article, "Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer," by researchers and Reata scientific collaborators from the Dartmouth Medical School Karen T. Liby, Mark M. Yore and Michael B. Sporn, focuses on two new classes of multifunctional drugs that it reports can prevent and treat cancer in experimental animals. One of Reata's lead clinical candidates, from one of the classes the article describes, the Synthetic Triterpenoids, is entering advanced clinical trials for deadly, late-stage cancers.

The article describes the Synthetic Triterpenoids as a new class of non-toxic and highly multifunctional drugs that have applications for the prevention and treatment of not only cancer, but also of many other diseases with an inflammatory component.

"An outstanding body of work is emerging on the Synthetic Triterpenoids from many top academic collaborators," commented Warren Huff, Reata's CEO. "Dr. Sporn and his team have provided an excellent summary of the broad research currently underway on these compounds and the underlying biological pathways they modulate. Reata is delighted to have the opportunity to collaborate with these researchers in taking take these important new drugs forward to provide a clinical benefit for patients with cancer and other diseases."

Reata in-licensed the complete series of Synthetic Triterpenoids from Dartmouth and the University of Texas M.D. Anderson Cancer Center in 2004. RTA 402, the lead agent from this series, has recently begun Phase 2 clinical studies for cancer and anti-inflammatory diseases. An ongoing Phase 1 study in cancer patients has demonstrated
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature
4. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
5. Critical Therapeutics Announces the Publication of New Preclincial HMGB1 Data in Nature Immunology
6. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
7. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
8. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
11. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Reata Synthetic Triterpenoids Profiled Nature Reviews Cancer
(Date:12/24/2014)... and FARMINGTON, Conn. ... Inc. (NYSE MKT: PTN), a biopharmaceutical company developing ... diseases with significant unmet medical need and commercial ... a private placement of 2,050,000 shares of its ... 24,949,325 shares of its common stock.  Funds under ...
(Date:12/24/2014)... , Dec. 23, 2014  Advanced Medical Isotope ... engaged primarily in the development of brachytherapy devices ... today announced that it has filed a ... Drug Administration ("FDA") for marketing clearance for its ... of the U.S. Food, Drug and Cosmetic Act ...
(Date:12/24/2014)...   Assurex Health, a personalized medicine company ... for behavioral health and chronic pain conditions, today ... equity financing from new and existing investors, according ... Chief Executive Officer. The financing will ... Health,s GeneSight ®  products.  GeneSight,s patented ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... July 12 Endo Pharmaceuticals (Nasdaq: ENDP ) today ... offer by its wholly owned subsidiary, HT Acquisition Corp., for all ... HTRN).  American Stock Transfer & Trust Company, the depositary for the ... , New York City time, on July 9, ...
... 12 Signum Biosciences announced that its ... Medirepair® with Signum,s compound Arazine™ (n-acetyl-s-farnsylcysteine or AFC) ... compound from Signum,s novel anti-inflammatory platform to be ... (STMs). The DRx AFC Medirepair® website can be ...
Cached Medicine Technology:Endo Pharmaceuticals Announces Expiration of Subsequent Offering Period of Tender Offer for HealthTronics, Inc. 2Endo Pharmaceuticals Announces Expiration of Subsequent Offering Period of Tender Offer for HealthTronics, Inc. 3Endo Pharmaceuticals Announces Expiration of Subsequent Offering Period of Tender Offer for HealthTronics, Inc. 4Signum Biosciences, Inc. Announces Commercial Launch of Arazine™ 2Signum Biosciences, Inc. Announces Commercial Launch of Arazine™ 3
(Date:12/26/2014)... December 26, 2014 It is said that ... dress. Today, UWDress.com, the famous wedding dress supplier, shows ... a site-wide cocktail gown promotion. , UWDress.com’s navy cocktail ... and they come in high fashion styles. Simple dresses in ... on the occasion; they are specially designed for those who ...
(Date:12/26/2014)... 2014 Yisrayl Hawkins, Pastor at The House ... in light of the Ferguson, Missouri unrest. Yisrayl starts his ... and explains why it has only increased. , He ... created. He says there is a very specific reason for ... there is a set of rules, or Laws that if ...
(Date:12/26/2014)... 26, 2014 Plugin and template developers from ... 5 Plugin for Final Cut Pro X. , “TransPack Volume ... tool to pull off an industry professional look” Said Christina ... hands on TransPack Volume 5, a new level of professionalism ... set of over 50 Final Cut Pro X transitions featuring ...
(Date:12/26/2014)... India Network Foundation, a non-profit US based ... today a new version of “ EasySelect ”, a ... plan for their visiting parents. The technology tool is ... process when choosing an insurance plan by showing the ... few clicks. Many elderly Asian Indian parents often find ...
(Date:12/26/2014)... (DaWei Induction Heating Co.) is a comprehensive high-tech business ... of a series of induction heating equipment. Today, the ... induction brazing equipments . , According to a ... refers to the joining of two or more components ... says that there are fundamental differences in the two ...
Breaking Medicine News(10 mins):Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2
... HealthDay Reporter , THURSDAY, April 14 (HealthDay News) ... cancer survivors after successful treatment stems from a tug ... the autonomic nervous system, with the former working overtime ... new study suggests. Researchers from Ohio State University ...
... Calif., April 14, 2011 New survey data released ... 20th Annual Meeting and Clinical Congress reveal that more ... across the country report they have experienced hypoglycemia, or ... typical daily activities such as working (42%), exercising (26%) ...
... Institute today announced a collaboration and strategic agreement ... rapid development of a vaccine and accelerate preparedness ... as pandemic influenza. The team, composed of Duke ... National Institute of Allergy and Infectious Diseases-sponsored Regional ...
... by researchers at the University of Alberta shows that for ... as well as prolonged exercise is the key to the ... of Rehabilitation Medicine, and Alex Clark, researcher in the Faculty ... Schopflocher in the School of Public Health, and Ian Paterson ...
... , THURSDAY, April 14 (HealthDay News) -- Parents who ... setting a bad example; they,re actually helping the children learn ... children ages 18 to 30 months found that older children ... when a voice explaining the item stumbled and said, "Look ...
... INDIANAPOLIS With mounting evidence that patient-centered care ... and Indiana University School of Medicine are providing ... future physicians to master relationship skills as well ... 21st Century medicine. "Crossing the ...
Cached Medicine News:Health News:Nervous System Imbalance May Cause Fatigue in Breast Cancer Survivors 2Health News:Nervous System Imbalance May Cause Fatigue in Breast Cancer Survivors 3Health News:New ACE survey shows people with type 2 diabetes experience low blood sugar during typical daily activities 2Health News:New ACE survey shows people with type 2 diabetes experience low blood sugar during typical daily activities 3Health News:Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines 2Health News:Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines 3Health News:Heart needs work after heart attack: U of A Study challenges the notion that the heart must rest 2Health News:Training future doctors to enlist patients as partners in care 2
... Are offered as either EDTA ... binds the calcium ions and therefore ... and thrombocytes in an EDTA anticoagulated ... to 24 hours. EDTA tubes are ...
... Tissue transglutaminase (tTg) is a ubiquitous ... proteins. Tissue transglutaminase is also the ... the endomysial antibody immunofluorescence (EMA) tests ... Anti-tTg IgA and,IgG serologic tests are ...
... staff gets the training it needs with ... System and Human Capital Management System in ... requirements for JCAHO and HIPAA, understanding compliance ... or developing skills through continuing education courses, ...
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
Medicine Products: